Clopidogrel and Kombiglyze xr drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Clopidogrel and Kombiglyze xr. Common interactions include cardiac failure congestive among females and cardiac failure congestive among males.

The phase IV clinical study analyzes what interactions people who take Clopidogrel and Kombiglyze xr have. It is created by eHealthMe based on reports of 43 people who take Clopidogrel and Kombiglyze xr from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 24, 2023

43 people who take Clopidogrel and Kombiglyze xr together, and have interactions are studied.

What is Clopidogrel?

Clopidogrel has active ingredients of clopidogrel. It is often used in blood clots. eHealthMe is studying from 79,618 Clopidogrel users for its effectiveness, alternative drugs and more.

What is Kombiglyze xr?

Kombiglyze xr has active ingredients of metformin hydrochloride; saxagliptin. It is often used in diabetes. eHealthMe is studying from 2,613 Kombiglyze xr users for its effectiveness, alternative drugs and more.

Number of Clopidogrel and Kombiglyze xr reports submitted per year:

Common Clopidogrel and Kombiglyze Xr drug interactions by gender *:

female:

Cardiac failure congestive
Cardiac failure
Chronic kidney disease
Cardiovascular disorder
Renal failure
Renal injury
Blood glucose increased
Bone disorder
Dyskinesia
Gastritis

male:

Cardiac failure congestive
Cardiac failure
Coronary artery occlusion
Coronary artery stenosis
Drug ineffective
Dysuria
Fall
Hypertension
Incisional hernia
Left ventricular failure

Common Clopidogrel and Kombiglyze Xr drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Cardiac failure
Cardiac failure congestive
Cardiomyopathy
Cardiovascular disorder
Coronary artery disease

50-59:

Cardiac failure congestive
Cardiac failure
Coronary artery disease
Cardiovascular disorder
Coronary artery stenosis
Chronic left ventricular failure
Diastolic dysfunction
Ischaemic cardiomyopathy
Acute left ventricular failure
Left ventricular failure

60+:

Cardiac failure congestive
Cardiac failure
Blood glucose increased
Weight decreased
Renal injury
Bone disorder
Dyskinesia
Gastritis
Hyperkeratosis
Influenza

Common conditions people have *:

Type 2 Diabetes: 21 people, 48.84%
High Blood Pressure: 6 people, 13.95%
High Blood Cholesterol: 6 people, 13.95%
Pain: 5 people, 11.63%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 9.30%
Cardiac Disorder: 3 people, 6.98%

* Approximation only. Some reports may have incomplete information.

Do you take Clopidogrel and Kombiglyze xr?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Lai SW, Lin CL, Liao KF, "Actively using clopidogrel correlates with an increased risk of acute pancreatitis in Taiwan", International journal of cardiology, 2015 Mar .
Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM, Barnato SE, Winters JL, Cursio JF, Weiss I, "Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR)", InSeminars in thrombosis and hemostasis, 2012 Jan .
Frank P, "Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty-Year Review from the Southern Network on Adverse Reactions (SONAR)", , 2012 Jan .